ATRA
Bullish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 0.82 · operating margin 30% — readings disagree
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Interesting trend — weekly bias down
ACHAT TOTAL: 104 166 titres (~999 993,60 $ US) VENTE TOTALE: 5 062 titres (~40 882,74 $ US)
- Insiders
- Cherry Brian NNguyen AnhCo
- Total bought
-
$999,994
Avg buy (VWAP, 90d window) $9.60 vs last close $8.81 (-8.2%)
- Total sold
-
$40,883
Avg sell (VWAP, 90d window) $8.08 vs last close $8.81 (+9.1%)
- Last activity
- 2026-09-04
- Liquidity
- Illiquid $410,305/day · 20d vol
- Last synced
-
2026-09-25 21:10:09
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-04 | Cherry Brian N | Buy | 104,166 | $9.60 | $999,994 | Form 4 |
| 2026-08-17 | Nguyen AnhCo | Sell | 5,062 | $8.08 | $40,883 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bullish signalScored 2026-09-20
ATRA shows a meaningful turnaround signal with a strong insider cluster buy (~$1M) following positive Q2 2026 earnings, suggesting informed confidence in the T-cell immunotherapy pipeline.
The first sentence of the analysis written for ATRA on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 82.4% | 83.7% | -3.7% | -324.7% | -1286.4% | |
| Ebit Margin | 30.2% | -62.7% | -3159.1% | -358.5% | -1672.1% | |
| Ebitda Margin | 32.0% | -58.7% | -3102.7% | -349.6% | -1626.1% | |
| Operating Profit Margin | 29.7% | -64.7% | -3219.5% | -441.2% | -1673.9% | |
| Pretax Profit Margin | 27.1% | -66.2% | -3220.7% | -359.1% | -1672.1% | |
| Continuous Operations Profit Margin | 27.1% | -66.2% | -3220.9% | -359.1% | -1672.3% | |
| Net Profit Margin | 27.1% | -66.2% | -3220.9% | -359.1% | -1672.3% | |
| Bottom Line Profit Margin | 27.1% | -66.2% | -3220.9% | -359.1% | -1672.3% | |
| Current Ratio | 0.818 | 0.482 | 0.716 | 3.739 | 3.636 | |
| Quick Ratio | 0.818 | 0.403 | 0.648 | 3.719 | 3.636 | |
| Solvency Ratio | 0.593 | -0.389 | -1.025 | -0.891 | -1.755 | |
| Cash Ratio | 0.568 | 0.186 | 0.182 | 1.178 | 1.003 | |
| Price To Earnings Ratio | 6.931 | -1.167 | -0.197 | -1.465 | -4.340 | |
| Price To Earnings Growth Ratio | -0.056 | 0.014 | -0.012 | 0.038 | 0.350 | |
| Forward Price To Earnings Growth Ratio | -0.056 | 0.014 | -0.012 | 0.038 | 0.350 | |
| Price To Earnings Diluted Ratio | 7.039 | -1.167 | -0.197 | -1.465 | -4.340 | |
| Price To Earnings Diluted Growth Ratio | -0.057 | 0.014 | -0.012 | 0.038 | 0.350 | |
| Price To Book Ratio | -5.894 | -1.024 | -0.547 | 2.642 | 5.280 | |
| Price To Sales Ratio | 1.879 | 0.773 | 6.335 | 5.262 | 72.578 | |
| Price To Free Cash Flow Ratio | -4.455 | -1.445 | -0.280 | -1.218 | -6.388 | |
| Price To Operating Cash Flow Ratio | -4.455 | -1.450 | -0.281 | -1.237 | -6.694 | |
| Debt To Assets Ratio | 2.609 | 0.402 | 0.350 | 0.190 | 0.060 | |
| Debt To Equity Ratio | -1.371 | -0.451 | -0.583 | 0.566 | 0.101 | |
| Debt To Capital Ratio | 3.693 | -0.820 | -1.399 | 0.362 | 0.092 | |
| Long Term Debt To Capital Ratio | -5.605 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | -0.526 | -1.121 | -1.668 | 2.972 | 1.674 | |
| Working Capital Turnover Ratio | -3.337 | -2.344 | 0.098 | 0.257 | 0.057 | |
| Operating Cash Flow Ratio | -3.414 | -0.511 | -1.357 | -3.427 | -2.085 | |
| Operating Cash Flow Sales Ratio | -0.422 | -0.533 | -22.510 | -4.254 | -10.842 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.004 | 1.006 | 1.016 | 1.048 | |
| Debt Service Coverage Ratio | 2.649 | -16.411 | -50.333 | -595.914 | 0.000 | |
| Interest Coverage Ratio | 9.457 | -18.080 | -52.224 | -752.046 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -4.726 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.965 | -1.568 | -3.335 | -3.771 | -7.800 | |
| Capital Expenditure Coverage Ratio | 0.000 | -279.337 | -157.790 | -64.496 | -20.843 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -279.337 | -157.790 | -64.496 | -20.843 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 7.022 | -1.564 | -0.325 | -1.410 | -4.228 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 82.4% | ▼-1.3% | ▲372.2% |
| Ebit Margin | 30.2% | ▲92.9% | ▲1074.6% |
| Ebitda Margin | 32.0% | ▲90.7% | ▲1053.0% |
| Operating Profit Margin | 29.7% | ▲94.4% | ▲1103.6% |
| Pretax Profit Margin | 27.1% | ▲93.3% | ▲1085.3% |
| Continuous Operations Profit Margin | 27.1% | ▲93.3% | ▲1085.4% |
| Net Profit Margin | 27.1% | ▲93.3% | ▲1085.4% |
| Bottom Line Profit Margin | 27.1% | ▲93.3% | ▲1085.4% |
| Current Ratio | 0.818 | ▲0.336 | ▼-1.060 |
| Quick Ratio | 0.818 | ▲0.415 | ▼-1.026 |
| Solvency Ratio | 0.593 | ▲0.982 | ▲1.286 |
| Cash Ratio | 0.568 | ▲0.382 | ▼-0.055 |
| Price To Earnings Ratio | 6.931 | ▲8.098 | ▲6.979 |
| Price To Earnings Growth Ratio | -0.056 | ▼-0.070 | ▼-0.123 |
| Forward Price To Earnings Growth Ratio | -0.056 | ▼-0.070 | ▼-0.123 |
| Price To Earnings Diluted Ratio | 7.039 | ▲8.205 | ▲7.065 |
| Price To Earnings Diluted Growth Ratio | -0.057 | ▼-0.072 | ▼-0.124 |
| Price To Book Ratio | -5.894 | ▼-4.869 | ▼-5.985 |
| Price To Sales Ratio | 1.879 | ▲1.106 | ▼-15.486 |
| Price To Free Cash Flow Ratio | -4.455 | ▼-3.010 | ▼-1.698 |
| Price To Operating Cash Flow Ratio | -4.455 | ▼-3.004 | ▼-1.631 |
| Debt To Assets Ratio | 2.609 | ▲2.208 | ▲1.887 |
| Debt To Equity Ratio | -1.371 | ▼-0.921 | ▼-1.024 |
| Debt To Capital Ratio | 3.693 | ▲4.513 | ▲3.308 |
| Long Term Debt To Capital Ratio | -5.605 | ▼-5.605 | ▼-4.484 |
| Financial Leverage Ratio | -0.526 | ▲0.596 | ▼-0.792 |
| Working Capital Turnover Ratio | -3.337 | ▼-0.993 | ▼-2.283 |
| Operating Cash Flow Ratio | -3.414 | ▼-2.903 | ▼-1.255 |
| Operating Cash Flow Sales Ratio | -0.422 | ▲0.111 | ▲7.290 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.004 | ▼-0.015 |
| Debt Service Coverage Ratio | 2.649 | ▲19.060 | ▲134.651 |
| Interest Coverage Ratio | 9.457 | ▲27.537 | ▲172.036 |
| Short Term Operating Cash Flow Coverage Ratio | -4.726 | ▼-4.726 | ▼-3.781 |
| Operating Cash Flow Coverage Ratio | -0.965 | ▲0.603 | ▲2.523 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲279.337 | ▲104.493 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲279.337 | ▲104.493 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 7.022 | ▲8.586 | ▲7.123 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $226.9M | $99.7M | $54.3M | $334.5M | $1.48B | |
| Enterprise value | $271.2M | $118.5M | $86.3M | $313.3M | $1.40B | |
| EV / Sales | 2.25x | 0.92x | 10.07x | 4.93x | 68.75x | |
| EV / Op. cash flow | -5.33x | -1.72x | -0.45x | -1.16x | -6.34x | |
| EV / Free cash flow | -5.33x | -1.72x | -0.45x | -1.14x | -6.05x | |
| EV / EBITDA | 7.02x | -1.56x | -0.33x | -1.41x | -4.23x | |
| Net debt / EBITDA | 1.15x | -0.25x | -0.12x | 0.10x | 0.23x | |
| Current ratio | 0.82x | 0.48x | 0.72x | 3.74x | 3.64x | |
| Income quality | -1.56x | 0.81x | 0.70x | 1.19x | 0.65x | |
| Graham net-net | -$4 | -$21 | -$43 | $6 | $49 | |
| Tax burden | 99.9% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 89.6% | 105.7% | 102.0% | 100.2% | 100.0% | |
| Working capital | -$2.7M | -$69.7M | -$40.4M | $216.2M | $278.8M | |
| Invested capital | $4.4M | -$28.6M | $18.4M | $290.5M | $358.8M | |
| Return on assets | 161.5% | -78.3% | -166.8% | -60.7% | -72.7% | |
| Operating ROA | 55.5% | -60.8% | -101.9% | -66.4% | -64.5% | |
| Return on tangible assets | 161.5% | -78.3% | -166.8% | -60.7% | -72.7% | |
| Return on equity | -84.9% | 87.8% | 278.3% | -180.3% | -121.6% | |
| Return on invested capital | 222.7% | 721.7% | -778.4% | -90.2% | -93.3% | |
| Return on capital employed | 675.0% | 327.5% | -1185.7% | -94.3% | -94.0% | |
| Earnings yield | 14.4% | -85.7% | -508.4% | -68.2% | -23.0% | |
| Free cash flow yield | -22.4% | -69.2% | -357.6% | -82.1% | -15.7% | |
| Capex / Op. cash flow | 0.0% | -0.4% | -0.6% | -1.6% | -4.8% | |
| Capex / Depreciation | 0.0% | 4.9% | 25.3% | 74.2% | 113.2% | |
| Capex / Sales | 0.0% | 0.2% | 14.3% | 6.6% | 52.0% | |
| SG&A / Sales | 21.7% | 30.9% | 593.8% | 107.2% | 387.4% | |
| R&D / Sales | 31.0% | 117.5% | 2622.0% | 428.7% | 1386.4% | |
| Stock comp / Sales | 8.1% | 20.9% | 529.4% | 84.7% | 264.8% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 4d | 4d | 1452d | 231d | 18d | |
| Days payables outstanding | 2d | 76d | 151d | 9d | 22d | |
| Operating cycle | 4d | 189d | 1851d | 233d | 18d | |
| Cash conversion cycle | 2d | 113d | 1700d | 224d | -5d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+127.7%EV / Sales ▲+144.4%EV / EBITDA ▲+549.0%EV / Op. cash flow ▼-3.601Earnings yield ▲+1.001
Profitability
Return on equity ▼-1.727Return on assets ▲+2.398Return on invested capital ▼-4.991Return on capital employed ▲+3.475Operating ROA ▲+1.162Income quality ▼-2.363Tax burden ▼-0.001
Efficiency
Days sales outstanding ▼-0.408Days payables outstanding ▼-73.685Operating cycle ▼-185.523Cash conversion cycle ▼-111.838Capex / Sales ▼-0.002R&D / Sales ▼-0.865
Balance-sheet strength
Current ratio ▲+0.336Net debt / EBITDA ▲+1.395Working capital ▲+66970000.000Invested capital ▲+33006000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-84.6%EV / Sales ▼-96.7%EV / EBITDA ▲+266.1%EV / Op. cash flow ▲+1.017Earnings yield ▲+0.374
Profitability
Return on equity ▲+0.367Return on assets ▲+2.342Return on invested capital ▲+3.159Return on capital employed ▲+7.689Operating ROA ▲+1.199Income quality ▼-2.207Tax burden ▼-0.001
Efficiency
Days sales outstanding ▼-13.907Days payables outstanding ▼-20.294Operating cycle ▼-13.907Cash conversion cycle ▲+6.388Capex / Sales ▼-0.520R&D / Sales ▼-13.554
Balance-sheet strength
Current ratio ▼-2.817Net debt / EBITDA ▲+0.912Working capital ▼-281545000.000Invested capital ▼-354347000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-12 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates. “This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with the.
- 2026-06-12 Atara Biotherapeutics Announces Changes to Its Board of Directors THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors. “On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its share.
- 2026-06-11 Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in QUATRO-APL, the company''s global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), for the treatment of patients with newly diagnosed, low-risk Acute Promyelocytic Leukemia, or APL.